Epifysiodesis for adolescents; What is the most effective postoperative pain treatment? An RCT

Published: 23-03-2015 Last updated: 19-03-2025

What is the effectiveness of an epidural painmanagement compared with a PCA method as postoperative treatment after an epiphysiodesis for adolescents during the first 5 days after

the procedure?

Ethical review Approved WMO **Status** Completed

Health condition type Bone disorders (excl congenital and fractures)

Study type Interventional

Summary

ID

NL-OMON42155

Source

ToetsingOnline

Brief title

Postoperative pain treatment after epiphysiodesis

Condition

Bone disorders (excl congenital and fractures)

Synonym

postoperative pain; pain after epiphysiodesis

Research involving

Human

Sponsors and support

Primary sponsor: Maxima Medisch Centrum

Source(s) of monetary or material Support: Maatschap Orthopedie

Intervention

Keyword: adolescent, epiphysiodesis, pain treatment, RCT

Outcome measures

Primary outcome

The primary outcome is the VAS (visual analoge scores) for pain during the first 5 days after the procedure.

Secondary outcome

Secundary outcome measures are: amount of pain 2 weeks, 6 weeks and 6 months after the procedure; co-medication use; adverse events; satisfaction rate of the patient; duration of Hospital stay and knee function.

Study description

Background summary

An epiphysiodesis of the knee is a frequently performed procedure for adolescents in Maxima MC. Since three year both departments of Orthopedic surgery of Maxima MC and Catharina Hospital has formed one membership, and as consequent from this there are two different postoperatiev pain management protocols active. Namely a) an epidural pain protocol and b) a PCA (pain pump). Both painmanagement protocol will be compared.

Study objective

What is the effectiveness of an epidural painmanagement compared with a PCA method as postoperative treatment after an epiphysiodesis for adolescents during the first 5 days after the procedure?

Study design

open-labeled randomized clinical trial

Intervention

a) epidural painmanagement will be started at the beginning of the surgical procedure and will be in situ for three days. Thereafter painmedication will be prescribed according to the WHO; b) painmanagement with the use of a PCA (pain pump) started directly after the surgical procedure, eventually oral medication according to the WHO will be given.

Study burden and risks

Both pain management protocols are currently used in Maxima MC. The VAS is used as standard evaluation tool during the Hospital period. During the standard visits of the outpatient clinic we ask additional time of the patient to fill in two questionnaires.

Contacts

Public

Maxima Medisch Centrum

ds. Th. Fliednerstraat 1 Eindhoven 5631 BM NL

Scientific

Maxima Medisch Centrum

ds. Th. Fliednerstraat 1 Eindhoven 5631 BM NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adolescents (12-15 years) Adolescents (16-17 years)

Inclusion criteria

age between12-16 year; *indicated for an epiphysiodesis*, namele boys of which the estimated finally body length will be minimally 200 cm; and for girls 195 cm.

Exclusion criteria

insufficient command of Dutch language; not willing to be randomized; contra-indications for an epiphysiodesis procedure.

Study design

Design

Study phase: 4

Study type: Interventional

Intervention model: Parallel

Allocation: Randomized controlled trial

Masking: Open (masking not used)

Control: Active

Primary purpose: Treatment

Recruitment

NL

Recruitment status: Completed

Start date (anticipated): 01-10-2015

Enrollment: 70

Type: Actual

Medical products/devices used

Product type: Medicine

Brand name: Bupivacaïne Actavis

Generic name: Bupivacaïne

Registration: Yes - NL intended use

Product type: Medicine

Brand name: Morfine HCl CF

Generic name: Morfine

Registration: Yes - NL intended use

Ethics review

Approved WMO

Date: 23-03-2015

Application type: First submission

Review commission: METC Maxima Medisch Centrum (Veldhoven)

Approved WMO

Date: 26-03-2015

Application type: First submission

Review commission: METC Maxima Medisch Centrum (Veldhoven)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

ID: 24503

Source: Nationaal Trial Register

Title:

In other registers

Register ID

EudraCT EUCTR2015-000870-36-NL

CCMO NL50837.015.15 OMON NL-OMON24503

Study results

Date completed: 15-02-2017

Summary results

Trial ended prematurely